You are here:

mirabegron (Betmiga)

Advice

following a full submission:

mirabegron (Betmiga®) is accepted for use within NHS Scotland.

Indication under review: for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.

Mirabegron was associated with modest treatment benefits over placebo in reducing symptoms associated with overactive bladder syndrome, including frequency and incontinence.

Alternative treatments are available at a lower drug acquisition cost.

Drug Details

Drug Name: mirabegron (Betmiga)
SMC Drug ID: 862/13
Manufacturer: Astellas Pharma Ltd
Indication: For symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
BNF Category:
Sub Category: 7.4 Drugs for genito-urinary disorders
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 May 2013

Back